Smith & Nephew ADR saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 63 to 71.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an RS Rating of over 80 in the early stages of their moves. See if Smith & Nephew ADR can continue to show renewed price strength and clear that threshold.
Smith & Nephew ADR is working on a consolidation with a 31.72 buy point. See if the stock can clear the breakout price in heavy trade.
Smith & Nephew ADR showed -2% EPS growth in the latest quarterly report, while sales growth came in at 6%.
The company earns the No. 26 rank among its peers in the Medical-Products industry group. Insulet, Boston Scientific and LifeMD are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
